BioStem has developed three perinatal tissue allograft products for wound care — Vendaje®, Vendaje AC®, and Vendaje Optic® — intended for homologous use as a protective covering for soft-tissue wounds. The company says its initial commercial strategy heavily focuses on its products being sold and reimbursed within the Medicare system.
Pricing Provides VENDAJETM Reimbursement in All MAC RegionsPOMPANO BEACH, FLORIDA., Jan. 24, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTCQB: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, announced that the Center for Medicare Services (“CMS”) has established national pricing of VENDAJETM in all Medicare Administrative Contractors (MAC) regions, effective January 1, 2023.
